Last reviewed · How we verify
TDAP
At a glance
| Generic name | TDAP |
|---|---|
| Also known as | tetanus, diptheria, and pertussis vaccination, Boostrix, Adacel, GSK Boostrix, Adacel |
| Sponsor | VA Office of Research and Development |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Pain at injection site
- Headache
- Erythema
- Swelling
- Fever (≥38°C)
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) (PHASE1)
- A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control (PHASE3)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Safety Monitoring of Boostagen® Vaccine in Thailand
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDAP CI brief — competitive landscape report
- TDAP updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI